Oligonucleotide-based strategies to combat polyglutamine diseases

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Polyglutamine (polyQ) diseases share common molecular pathogenic mechanisms involving mutant protein and RNA toxicity.
• Therapeutic strategies are advancing, with a focus on targeting gene expression early in disease pathogenesis.

Purpose of the Study:

• To review the use of oligonucleotide (ON)-based tools, including antisense oligonucleotides (ASOs) and RNA interference (RNAi) triggers, for treating polyQ diseases.
• To compare different gene silencing strategies (non-allele-selective and allele-selective) in cellular and animal models.

Main Methods:

• Review of studies utilizing ASOs and RNAi triggers for experimental treatment of polyQ diseases.
• Analysis of allele-selective strategies targeting SNPs or expanded CAG repeats.
• Comparison of gene silencing effectors based on design, efficiency in cell culture, and preclinical testing.

Main Results:

• Oligonucleotide-based tools are effective in reducing mutant gene expression in preclinical models of polyQ diseases.
• Both non-allele-selective and allele-selective silencing strategies have been explored.
• Allele-selective approaches offer potential for greater specificity by targeting specific mutations or repeat expansions.

Conclusions:

• ON-based gene silencing represents a promising therapeutic avenue for polyQ diseases.
• Further research is needed to optimize ON design, delivery, and efficacy, and to address current limitations for clinical translation.